OncoMatch/Clinical Trials/NCT06496178
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Is NCT06496178 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Petosemtamab and Investigator's Choice for head and neck squamous cell carcinoma.
Treatment: Petosemtamab · Investigator's Choice · Investigator's Choice · Investigator's Choice — This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: CDKN2A p16 status (positive or negative) by IHC
Documentation of p16 status (positive or negative) by local laboratory IHC for patients with primary oropharyngeal cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy
HNSCC patients progressed on or after anti-PD-1 therapy
Must have received: platinum-based chemotherapy
HNSCC patients progressed on or after...platinum-containing therapy
Cannot have received: systemic anticancer therapy
Any systemic anticancer therapy within 4 weeks of the first dose of study treatment
Lab requirements
Blood counts
adequate organ function (as per protocol)
Kidney function
adequate organ function (as per protocol)
Liver function
adequate organ function (as per protocol)
Adequate organ function (as per protocol)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Site 94 · Pearland, Texas
- Site 160 · Mobile, Alabama
- Site 102 · Prescott, Arizona
- Site 125 · Scottsdale, Arizona
- Site 82 · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify